Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )
4 Jun 2022

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

Dr Roy Herbst - Yale Cancer Center, New Haven, USA
Ramucirumab plus pembrolizumab improves OS in advanced NSCLC ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )
4 Jun 2022

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL (  )
3 Jun 2022

Pre-operative risk factors associated with peri-operative psychiatric diagnosis in oral cancer patients

Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India
Pre-operative risk factors associated with peri-operative psychiatric diagnosis in oral cancer patients ( Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India )
25 May 2022

COMy 2022: Multiple myeloma roundup

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
COMy 2022: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
24 May 2022

Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
10 May 2022

Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma

Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, USA
Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma ( Prof Yago Nieto - The University of Texas MD Anderson Cancer Center, Houston, USA )
26 Apr 2022

Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC

Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl
Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC ( Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl )
21 Apr 2022

Recurrent non-invasive breast tumours may not always be related to the primary lesion

Dr Tanjina Kader - University of Melbourne, Melbourne, Australia
Recurrent non-invasive breast tumours may not always be related to the primary lesion ( Dr Tanjina Kader - University of Melbourne, Melbourne, Australia )
19 Apr 2022

Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer

Prof Benoit You - Hospices Civils de Lyon, Lyon, France
Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )
14 Apr 2022

The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies

Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands
The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies ( Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands )
13 Apr 2022

Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022